×
About 5,670 results

ALLMedicine™ Acute Promyelocytic Leukemia Center

Research & Reviews  2,735 results

Arsenic trioxide in pediatric cancer - a case series and review of literature.
https://doi.org/10.1080/08880018.2021.1872748
Pediatric Hematology and Oncology; Abele M, Müller SL et. al.

Feb 26th, 2021 - Arsenic trioxide (ATO) has become an established component of treatment protocols for acute promyelocytic leukemia (APL) with excellent efficacy and no relevant sustained toxicity. Part of its action has been attributed to the inhibition of Hedgeh...

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide...
https://doi.org/10.1080/16078454.2021.1889159
Hematology (Amsterdam, Netherlands); Wu Y, Ke P et. al.

Feb 25th, 2021 - The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL). One...

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
https://doi.org/10.1002/ajh.26142
American Journal of Hematology; Fathi AT, Stein EM et. al.

Feb 24th, 2021 - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-rel...

Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870231
Medicine Sun Y, Wang C et. al.

Feb 17th, 2021 - The transformation of acute promyelocytic leukemia (APL) to acute mononuclear leukemia during treatment is a rare clinical phenomenon, and no CCAAT/enhancer-binding protein alpha (CEBPA) double mutations have been reported. A 42-year-old male was ...

Honokiol induces paraptosis-like cell death of acute promyelocytic leukemia via mTOR & ...
https://doi.org/10.1007/s10495-020-01655-9 10.1084/jem.20131121 10.1007/978-3-540-34594-7_7 10.1007/s12185-013-1354-4 10.1182/blood-2019-01-894980 10.1073/pnas.97.26.14376 10.1002/ijc.24064 10.1016/j.canlet.2008.05.008 10.1242/jcs.00994 10.1016/j.redox.2018.11.019 10.1016/j.cbi.2018.02.003 10.1016/j.pharmthera.2011.01.010 10.3390/cancers12010048 10.1016/j.bbrc.2012.12.063 10.2174/156652412803833508 10.1007/s10815-018-1353-8 10.1074/jbc.M303763200 10.1016/j.pharmthera.2016.01.003 10.1038/cddis.2013.85 10.1002/jcp.22956 10.1038/onc.2009.118 10.1002/cncr.31335 10.1038/cddis.2017.217 10.1096/fj.10-175158 10.1038/nchembio883 10.1007/s10637-018-0566-0 10.1038/s41419-017-0018-3 10.1016/j.freeradbiomed.2017.02.015 10.1038/cddis.2012.192 10.1016/j.phrs.2019.04.004 10.1056/NEJMoa1300874 10.3390/ijms19020448 10.3390/ijms19010132 10.1002/smll.201702446 10.1016/j.bbcan.2020.188338 10.1038/sj.cdd.4401465 10.1007/s00432-017-2464-9 10.3892/or.2020.7576 10.1002/jcp.25349 10.1039/c8dt00783g 10.1038/s41598-018-27724-3 10.1016/j.cbi.2019.108733 10.1038/s41419-019-1360-4 10.1111/cpr.12576
Apoptosis : an International Journal on Programmed Cell D... Liu X, Gu Y et. al.

Feb 7th, 2021 - Acute promyelocytic leukemia (APL) is a blood system disease caused by the accumulation of a large number of immature blood cells in bone marrow. Although the introduction of all-trans retinoic acid (ATRA) and arsenic has reached a high level of c...

see more →

Guidelines  2 results

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement o...
http://ascopubs.org/doi/10.1200/JCO.18.01468
de Haas, V.

Dec 2nd, 2018 - The College of American Pathologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline on the initial diagnostic work-up of acute leukemia (AL). Because of the relevance of this topic to the ASCO membership,.

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 13th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  2,835 results

Arsenic trioxide in pediatric cancer - a case series and review of literature.
https://doi.org/10.1080/08880018.2021.1872748
Pediatric Hematology and Oncology; Abele M, Müller SL et. al.

Feb 26th, 2021 - Arsenic trioxide (ATO) has become an established component of treatment protocols for acute promyelocytic leukemia (APL) with excellent efficacy and no relevant sustained toxicity. Part of its action has been attributed to the inhibition of Hedgeh...

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide...
https://doi.org/10.1080/16078454.2021.1889159
Hematology (Amsterdam, Netherlands); Wu Y, Ke P et. al.

Feb 25th, 2021 - The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL). One...

Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
https://doi.org/10.1002/ajh.26142
American Journal of Hematology; Fathi AT, Stein EM et. al.

Feb 24th, 2021 - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-rel...

Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870231
Medicine Sun Y, Wang C et. al.

Feb 17th, 2021 - The transformation of acute promyelocytic leukemia (APL) to acute mononuclear leukemia during treatment is a rare clinical phenomenon, and no CCAAT/enhancer-binding protein alpha (CEBPA) double mutations have been reported. A 42-year-old male was ...

Honokiol induces paraptosis-like cell death of acute promyelocytic leukemia via mTOR & ...
https://doi.org/10.1007/s10495-020-01655-9 10.1084/jem.20131121 10.1007/978-3-540-34594-7_7 10.1007/s12185-013-1354-4 10.1182/blood-2019-01-894980 10.1073/pnas.97.26.14376 10.1002/ijc.24064 10.1016/j.canlet.2008.05.008 10.1242/jcs.00994 10.1016/j.redox.2018.11.019 10.1016/j.cbi.2018.02.003 10.1016/j.pharmthera.2011.01.010 10.3390/cancers12010048 10.1016/j.bbrc.2012.12.063 10.2174/156652412803833508 10.1007/s10815-018-1353-8 10.1074/jbc.M303763200 10.1016/j.pharmthera.2016.01.003 10.1038/cddis.2013.85 10.1002/jcp.22956 10.1038/onc.2009.118 10.1002/cncr.31335 10.1038/cddis.2017.217 10.1096/fj.10-175158 10.1038/nchembio883 10.1007/s10637-018-0566-0 10.1038/s41419-017-0018-3 10.1016/j.freeradbiomed.2017.02.015 10.1038/cddis.2012.192 10.1016/j.phrs.2019.04.004 10.1056/NEJMoa1300874 10.3390/ijms19020448 10.3390/ijms19010132 10.1002/smll.201702446 10.1016/j.bbcan.2020.188338 10.1038/sj.cdd.4401465 10.1007/s00432-017-2464-9 10.3892/or.2020.7576 10.1002/jcp.25349 10.1039/c8dt00783g 10.1038/s41598-018-27724-3 10.1016/j.cbi.2019.108733 10.1038/s41419-019-1360-4 10.1111/cpr.12576
Apoptosis : an International Journal on Programmed Cell D... Liu X, Gu Y et. al.

Feb 7th, 2021 - Acute promyelocytic leukemia (APL) is a blood system disease caused by the accumulation of a large number of immature blood cells in bone marrow. Although the introduction of all-trans retinoic acid (ATRA) and arsenic has reached a high level of c...

see more →

News  77 results

How to Treat Differentiation Syndrome in APL and AML
https://decisionpoint.medscape.com/oncology/viewarticle/936167

Sep 17th, 2020 - This transcript has been edited for clarity. Differentiation syndrome is a frequent complication while patients have active acute promyelocytic leukemia (APL). First of all, we need to mention that the diagnosis of differentiation syndrome is base...

Don't Overlook Treating Older Patients With Acute Promyelocytic Leukemia, Expert Says
https://www.medscape.com/viewarticle/934124

Jul 16th, 2020 - The estimated one third of patients with acute promyelocytic leukemia (APL) who are older than 60 years of age now enjoy a notably better prognosis than in years past, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxi...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.staging.medscape.com/viewarticle/917519

Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

How a 100-Year-Old Formula Could Stop Lifesaving Cancer Therapy
https://www.medscape.com/viewarticle/917519

Aug 29th, 2019 - While leading his team on a hospital round, Joshua F. Zeidner, MD, saw a note recommending that arsenic trioxide (Trisenox, Teva) should be temporarily discontinued in a 44-year-old woman with acute promyelocytic leukemia (APL). The recommendation...

see more →